Drug profile · INN
docosanol
DOCOSANOL
docosanol (DOCOSANOL) is a envelope glycoprotein inhibitor. Route of administration: topical. Current US regulatory status: approved.
Drug details — docosanol
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
docosanol (DOCOSANOL) is a envelope glycoprotein inhibitor. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Envelope glycoprotein inhibitor
Primary target: Envelope glycoprotein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is docosanol?
docosanol (DOCOSANOL) is a envelope glycoprotein inhibitor. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for docosanol?
DOCOSANOL is a marketed brand name for docosanol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of docosanol?
docosanol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.